The initiation of a first-line AML trial with biomarker stratification increases the commercial and regulatory potential of SLS009. Traders should monitor enrollment progress and upcoming clinical updates, particularly as the Q4 2026 topline readout approaches. The strong r/r AML data supports continued investment in the CDK9 program.
Price Chart
Executive Summary
SELLAS Life Sciences has enrolled the first patient in a Phase 2 trial for its CDK9 inhibitor SLS009 (tambiciclib) in newly diagnosed AML patients unlikely to benefit from standard azacitidine/venetoclax therapy. The trial leverages the company's predictive biomarker and AI models, with topline data expected in Q4 2026. This follows positive Phase 2 results in relapsed/refractory AML, including a 40% ORR at the recommended dose and strong survival signals in high-risk subgroups.
Key Facts
- First patient enrolled in a randomized Phase 2 trial of SLS009 in first-line AML patients who are unlikely to respond to aza/ven therapy.
- Trial targets two high-unmet-need cohorts: biomarker-defined non-responders and early resistance patients.
- Phase 2 data in r/r AML showed 40% ORR at 30mg BIW dose, 50% ORR in ASXL1-mutated AML-MR, and median OS of 8.8 months vs 2.4 months with best available therapy.
- FDA encouraged advancement into first-line AML based on prior data.
- Topline data from the new study expected in Q4 2026.
Financial Impact
No direct financial impact disclosed; potential for future registrational pathway in first-line AML, a significantly larger market than r/r AML.
Risk Factors
- Clinical development risk: Phase 2 success in r/r AML does not guarantee efficacy in first-line setting.
- Long timeline to data: Topline results not expected until Q4 2026, increasing uncertainty and market risk over time.
- Competition: Aza/ven is standard of care; new therapies in AML are emerging.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254670 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $12.17 | awaiting T+60 | — | $12.17 (+0.00%) |
Sep 25, 2026 4w ago | Press Release | $11.61 | awaiting T+60 | — | $12.17 (+4.82%) |
Jun 2, 2026 21w ago | 8-K | $8.33 $13.73 | ▲ +64.83% | ▲ +63.71% | $12.17 (+46.10%) |
May 12, 2026 24w ago | 8-K | $6.53 $12.01 | ▲ +83.92% | ▲ +79.48% | $12.17 (+86.37%) |
Apr 23, 2026 26w ago | DEFA14A | $4.46 $12.90 | ▲ +189.24% | ▲ +184.16% | $12.17 (+172.87%) |
Mar 19, 2026 31w ago | Press Release | $4.76 $7.83 | ▲ +64.50% | ▲ +50.08% | $12.17 (+155.67%) |
Mar 17, 2026 32w ago | Press Release | $4.95 $7.75 | ▲ +56.57% | ▲ +45.04% | $12.17 (+145.86%) |
Mar 12, 2026 32w ago | Press Release | $5.03 $8.23 | ▲ +63.62% | ▲ +52.92% | $12.17 (+141.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers